A citation-based method for searching scientific literature

Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z Khokhar, Lisa O'Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau. N Engl J Med 2016
Times Cited: 891







List of co-cited articles
618 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
896
67

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach,[...]. N Engl J Med 2019
432
44

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Polina Kaplan,[...]. N Engl J Med 2018
548
36

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot,[...]. Lancet 2019
383
34

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen,[...]. N Engl J Med 2015
890
32

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos,[...]. Lancet 2019
242
30

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
A Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špička, Albert Oriol, Roman Hájek, Laura Rosiñol, David S Siegel, Georgi G Mihaylov,[...]. N Engl J Med 2015
884
29

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Henk M Lokhorst, Torben Plesner, Jacob P Laubach, Hareth Nahi, Peter Gimsing, Markus Hansson, Monique C Minnema, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo,[...]. N Engl J Med 2015
730
26

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson,[...]. N Engl J Med 2016
633
25

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten-Kumeli,[...]. Lancet 2020
148
25

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Sagar Lonial, Brendan M Weiss, Saad Z Usmani, Seema Singhal, Ajai Chari, Nizar J Bahlis, Andrew Belch, Amrita Krishnan, Robert A Vescio, Maria Victoria Mateos,[...]. Lancet 2016
552
24

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos,[...]. Lancet Oncol 2016
23

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Ajai Chari, Attaya Suvannasankha, Joseph W Fay, Bertrand Arnulf, Jonathan L Kaufman, Jainulabdeen J Ifthikharuddin, Brendan M Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo,[...]. Blood 2017
310
23

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
266
22

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S Raab,[...]. N Engl J Med 2018
260
22

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard,[...]. Lancet Haematol 2020
98
21

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Jakub Krejcik, Tineke Casneuf, Inger S Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W C J van de Donk, Brendan M Weiss,[...]. Blood 2016
489
20

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Marije B Overdijk, Sandra Verploegen, Marijn Bögels, Marjolein van Egmond, Jeroen J Lammerts van Bueren, Tuna Mutis, Richard W J Groen, Esther Breij, Anton C M Martens, Wim K Bleeker,[...]. MAbs 2015
308
19

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Peter M Voorhees, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson,[...]. Blood 2020
192
19

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Michele Cavo, Joan Blade, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy,[...]. Lancet 2020
167
18

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Ludek Pour, Roman Hájek, Thierry Facon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt,[...]. Lancet Oncol 2016
555
17

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson,[...]. Lancet Oncol 2014
17

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Paul G Richardson, Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Facon,[...]. Lancet Oncol 2019
146
17

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Michel Attal, Valerie Lauwers-Cances, Cyrille Hulin, Xavier Leleu, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret Macro, Karim Belhadj, Laurent Garderet,[...]. N Engl J Med 2017
589
16

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
Michel de Weers, Yu-Tzu Tai, Michael S van der Veer, Joost M Bakker, Tom Vink, Daniëlle C H Jacobs, Lukas A Oomen, Matthias Peipp, Thomas Valerius, Jerry W Slootstra,[...]. J Immunol 2011
618
16

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila,[...]. Lancet Oncol 2021
33
48

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Brian G M Durie, Antje Hoering, Muneer H Abidi, S Vincent Rajkumar, Joshua Epstein, Stephen P Kahanic, Mohan Thakuri, Frederic Reu, Christopher M Reynolds, Rachael Sexton,[...]. Lancet 2017
478
15

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
649
15

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
266
15

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Nizar J Bahlis, Meletios A Dimopoulos, Darrell J White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau,[...]. Leukemia 2020
79
17

Multiple myeloma.
Antonio Palumbo, Kenneth Anderson. N Engl J Med 2011
13

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Saad Z Usmani, Brendan M Weiss, Torben Plesner, Nizar J Bahlis, Andrew Belch, Sagar Lonial, Henk M Lokhorst, Peter M Voorhees, Paul G Richardson, Ajai Chari,[...]. Blood 2016
266
13

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
Marije B Overdijk, J H Marco Jansen, Maaike Nederend, Jeroen J Lammerts van Bueren, Richard W J Groen, Paul W H I Parren, Jeanette H W Leusen, Peter Boross. J Immunol 2016
163
13

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, Thierry Facon, Hartmut Goldschmidt, Andrzej Jakubowiak, Jesus San-Miguel, Mihaela Obreja, Julie Blaedel, A Keith Stewart. J Clin Oncol 2018
151
13

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Ajai Chari, Dan T Vogl, Maria Gavriatopoulou, Ajay K Nooka, Andrew J Yee, Carol A Huff, Philippe Moreau, David Dingli, Craig Cole, Sagar Lonial,[...]. N Engl J Med 2019
250
13

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar Bahlis,[...]. N Engl J Med 2014
538
12

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie-Lorraine Chretien, Thomas Dejoie, Sabrina Maheo, Anne-Marie Stoppa, Brigitte Pegourie,[...]. Blood 2018
192
11

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Antonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, Henk M Lokhorst, Hartmut Goldschmidt, Laura Rosinol, Paul Richardson, Simona Caltagirone, Juan José Lahuerta, Thierry Facon,[...]. J Clin Oncol 2015
919
11

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Meletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P Joy Ho, Kihyun Kim,[...]. Haematologica 2018
136
11

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Max S Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Krönke, Thierry Facon, Alexey V Salnikov, Robin Lesley,[...]. J Clin Oncol 2020
138
11

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra,[...]. Leukemia 2019
182
11

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, Lourdes Cordón, Maria-Teresa Cedena, Noemi Puig, Joaquin Martinez-Lopez, Laura Rosiñol, Norma C Gutierrez, María-Luisa Martín-Ramos,[...]. J Clin Oncol 2017
160
10

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi,[...]. Haematologica 2018
168
10

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Saad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W C J van de Donk, Ajai Chari, Jonathan L Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker,[...]. Blood 2019
56
17

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Jesus San Miguel, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol,[...]. Lancet Oncol 2013
547
10

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
304
10

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Philip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, Paul G Richardson, Cyrille Hulin, Patrizia Tosi, Sara Bringhen, Pellegrino Musto, Kenneth C Anderson, Denis Caillot,[...]. J Clin Oncol 2017
330
9

International uniform response criteria for multiple myeloma.
B G M Durie, J-L Harousseau, J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld,[...]. Leukemia 2006
9

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, Douglas Joshua, Wee-Joo Chng, Albert Oriol, Robert Z Orlowski, Heinz Ludwig, Thierry Facon, Roman Hajek,[...]. Lancet Oncol 2017
232
9

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Nikhil C Munshi, Herve Avet-Loiseau, Andy C Rawstron, Roger G Owen, J Anthony Child, Anjan Thakurta, Paul Sherrington, Mehmet Kemal Samur, Anna Georgieva, Kenneth C Anderson,[...]. JAMA Oncol 2017
269
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.